DK2544680T3 - USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER - Google Patents

USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER Download PDF

Info

Publication number
DK2544680T3
DK2544680T3 DK11730112T DK11730112T DK2544680T3 DK 2544680 T3 DK2544680 T3 DK 2544680T3 DK 11730112 T DK11730112 T DK 11730112T DK 11730112 T DK11730112 T DK 11730112T DK 2544680 T3 DK2544680 T3 DK 2544680T3
Authority
DK
Denmark
Prior art keywords
inhibitor
antibody
erbb3
seq
sequence
Prior art date
Application number
DK11730112T
Other languages
Danish (da)
English (en)
Inventor
Victor Moyo
Gabriela Garcia
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44513103&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2544680(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2544680T3 publication Critical patent/DK2544680T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK11730112T 2010-03-11 2011-03-11 USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER DK2544680T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31289510P 2010-03-11 2010-03-11
PCT/US2011/028129 WO2011112953A2 (en) 2010-03-11 2011-03-11 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers

Publications (1)

Publication Number Publication Date
DK2544680T3 true DK2544680T3 (en) 2015-04-27

Family

ID=44513103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11730112T DK2544680T3 (en) 2010-03-11 2011-03-11 USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

Country Status (21)

Country Link
US (4) US8895001B2 (es)
EP (2) EP2544680B1 (es)
JP (2) JP2013522237A (es)
KR (1) KR101798679B1 (es)
CN (1) CN102858335B (es)
AU (1) AU2011224186C1 (es)
BR (1) BR112012022802A2 (es)
CA (1) CA2792327C (es)
DK (1) DK2544680T3 (es)
EA (1) EA201201186A1 (es)
ES (1) ES2535503T3 (es)
HK (1) HK1174254A1 (es)
IL (1) IL221693A (es)
MX (1) MX344355B (es)
NZ (1) NZ602084A (es)
PL (1) PL2544680T3 (es)
PT (1) PT2544680E (es)
SG (1) SG183532A1 (es)
UA (1) UA111149C2 (es)
WO (1) WO2011112953A2 (es)
ZA (1) ZA201206425B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
KR20120098911A (ko) 2009-12-22 2012-09-05 로슈 글리카트 아게 항-ｈｅｒ3 항체 및 이의 용도
SG183532A1 (en) * 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CN105037552B (zh) 2010-08-20 2019-03-29 诺华股份有限公司 表皮生长因子受体3（her3)的抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR20140044796A (ko) * 2011-03-11 2014-04-15 메리맥 파마슈티컬즈, 인크. 호르몬 무반응 유방암의 치료에서 ｅｇｆｒ-패밀리 수용체의 저해제의 용도
KR102140984B1 (ko) 2011-03-31 2020-08-06 에이디씨 테라퓨틱스 에스에이 신장 결합 항원 １에 대한 항체 및 이의 항원 결합 단편
EA201490180A1 (ru) * 2011-06-30 2014-08-29 Мерримак Фармасьютикалз, Инк. Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
SG11201400150TA (en) 2011-09-30 2014-03-28 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
EP3974832A1 (en) * 2011-10-06 2022-03-30 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
AU2012323864A1 (en) 2011-10-13 2013-05-16 The Regents Of The University Of California Treatment of breast cancer with companion diagnostic
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP3533468A1 (en) * 2012-01-09 2019-09-04 ADC Therapeutics SA Method for treating breast cancer
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
EP2912062A1 (en) * 2012-10-24 2015-09-02 Yeda Research and Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
MX2015007054A (es) 2012-12-07 2016-01-12 Gen Hospital Corp Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015148971A2 (en) * 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
KR20170137886A (ko) 2015-04-17 2017-12-13 메리맥 파마슈티컬즈, 인크. 세리반투맙에 의한 병용 치료
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
CN105375955B (zh) * 2015-10-26 2018-07-17 西安电子科技大学 一种信能同传中继网络中的协作传输方法
KR101746152B1 (ko) 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
EP3866853A4 (en) * 2018-10-21 2022-08-03 SLSG Limited LLC MULTI-IMMUNOTHERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
WO2020161614A1 (en) * 2019-02-05 2020-08-13 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Methods for treating triple negative breast cancer using a human erbb-2 mutant protein
CN112755173B (zh) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法
US20220288204A1 (en) * 2021-03-11 2022-09-15 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6983227B1 (en) 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
CA2246429C (en) 1996-03-27 2007-07-24 Genentech, Inc. Erbb3 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
EP0938556B1 (en) 1996-07-12 2005-03-09 Genentech, Inc. Gamma-heregulin
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CA2443806A1 (en) 2000-04-14 2002-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
ES2334494T5 (es) * 2001-05-11 2013-05-29 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específicas y usos de las mismas
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
EP1421113A4 (en) 2001-08-03 2005-04-13 Commw Scient Ind Res Org SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
EP2400021B1 (en) 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. ErbB3 based methods and compositions for treating neoplasms
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
AU2003251597A1 (en) 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
DE03808454T1 (de) 2002-12-11 2006-01-26 Ventana Medical Systems, Inc., Tucson Verfahren zur voraussage der auswirkung der her2-gezielten therapie
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
JP4818917B2 (ja) 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
WO2005017493A2 (en) 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
US8554486B2 (en) 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
ES2425749T3 (es) 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
ES2677562T3 (es) 2004-05-27 2018-08-03 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
WO2005121380A1 (en) 2004-06-04 2005-12-22 Smithkline Beecham Corporation Predictive biomarkers in cancer therapy
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
JP2008532476A (ja) 2004-08-12 2008-08-21 ダイアックス コーポレーション 複合結合タンパク質
WO2006044378A2 (en) 2004-10-12 2006-04-27 University Of Iowa Research Foundation Rapid computational identification of targets
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
TW200642695A (en) 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20090298061A1 (en) 2005-07-29 2009-12-03 Siemens Healthcare Diagnostics Inc. Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy
WO2007041502A2 (en) 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
BRPI0520530A2 (pt) 2005-10-05 2009-09-29 Astrazeneca Uk Ltd método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
JP2009532393A (ja) 2006-04-07 2009-09-10 コペンハーゲン ユニバーシティ ＥｒｂＢ受容体由来ペプチド断片
US8367351B2 (en) 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
EP2047262A4 (en) 2006-07-13 2011-03-16 Univ Yale PROGNOSTIC METHODS OF CANCER FROM THE SUBCELLULAR LOCATION OF BIOMARKERS
US20100158894A1 (en) * 2006-09-15 2010-06-24 Tokai University Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
WO2008073629A2 (en) 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Bifunctional predictors of cancer treatment sensitivity and resistance
WO2008064884A1 (en) 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
NZ581201A (en) 2007-05-11 2012-05-25 Enzon Pharmaceuticals Inc Rna antagonist compounds for the modulation of her3
US20090054051A1 (en) 2007-08-22 2009-02-26 James Cavallo Attachable Headset for Portable Device
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
BR112012003809A2 (pt) 2009-08-21 2019-09-24 Merrimack Pharmaceuticals Inc anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
SG183532A1 (en) * 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
US8877687B2 (en) 2010-04-26 2014-11-04 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
AR084469A1 (es) 2010-07-09 2013-05-22 Exelixis Inc Combinaciones de inhibidores de quinasas para el tratamiento del cancer
FR2963868B1 (fr) 2010-08-11 2012-09-28 Valeo Systemes Thermiques Echangeur de chaleur comprenant un element chauffant serigraphie
US20140017264A1 (en) 2010-12-10 2014-01-16 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates
WO2012116317A2 (en) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR20140044796A (ko) * 2011-03-11 2014-04-15 메리맥 파마슈티컬즈, 인크. 호르몬 무반응 유방암의 치료에서 ｅｇｆｒ-패밀리 수용체의 저해제의 용도
EP2815765A1 (en) 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
CA2833643A1 (en) 2011-04-19 2012-10-26 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
EP2704746A2 (en) 2011-05-06 2014-03-12 Merrimack Pharmaceuticals, Inc. Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
AU2012273361A1 (en) 2011-06-24 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
EA201490180A1 (ru) 2011-06-30 2014-08-29 Мерримак Фармасьютикалз, Инк. Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
AU2012294326A1 (en) * 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
CA2868516A1 (en) 2012-04-02 2013-10-10 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3107578A2 (en) 2014-02-20 2016-12-28 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith

Also Published As

Publication number Publication date
PT2544680E (pt) 2015-05-06
US20150132292A1 (en) 2015-05-14
US20130034548A1 (en) 2013-02-07
JP2016166203A (ja) 2016-09-15
US8895001B2 (en) 2014-11-25
MX344355B (es) 2016-12-14
SG183532A1 (en) 2012-09-27
AU2011224186A1 (en) 2012-09-13
EP2544680B1 (en) 2015-01-14
WO2011112953A2 (en) 2011-09-15
EP2859893A1 (en) 2015-04-15
KR20130005280A (ko) 2013-01-15
CA2792327A1 (en) 2011-09-15
JP2013522237A (ja) 2013-06-13
EA201201186A1 (ru) 2013-11-29
PL2544680T3 (pl) 2015-08-31
US9518130B2 (en) 2016-12-13
AU2011224186C1 (en) 2015-04-02
EP2544680A2 (en) 2013-01-16
US20170291957A1 (en) 2017-10-12
CN102858335B (zh) 2015-04-15
NZ602084A (en) 2014-07-25
ZA201206425B (en) 2015-08-26
CN102858335A (zh) 2013-01-02
AU2011224186B2 (en) 2014-10-23
UA111149C2 (uk) 2016-04-11
IL221693A (en) 2015-10-29
US20190119401A1 (en) 2019-04-25
BR112012022802A2 (pt) 2018-05-15
ES2535503T3 (es) 2015-05-12
HK1174254A1 (en) 2013-06-07
CA2792327C (en) 2019-09-24
KR101798679B1 (ko) 2017-11-16
WO2011112953A3 (en) 2011-12-01
MX2012010226A (es) 2013-01-29
JP6185102B2 (ja) 2017-08-23

Similar Documents

Publication Publication Date Title
US20190119401A1 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
EP2815765A1 (en) Overcoming resistance to ERBB pathway inhibitors
EP3737696A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2022223006A1 (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers